Talk:Muscle-type nicotinic receptor

Wiki Education Foundation-supported course assignment

This article was the subject of a Wiki Education Foundation-supported course assignment, between 26 August 2020 and 18 December 2020. Further details are available on the course page. Student editor(s): Sultana24.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 01:17, 18 January 2022 (UTC)

Wiki Education Foundation-supported course assignment

This article was the subject of a Wiki Education Foundation-supported course assignment, between 28 January 2019 and 15 May 2019. Further details are available on the course page. Student editor(s): Shaque1228.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 04:38, 17 January 2022 (UTC)

Other agonists and partial agonists

Should we list other agonists such as nicotine and epibatidine? Also, what about adding a list of partial agonists?Shanata (talk) 07:18, 14 October 2010 (UTC)

External links modified (February 2018)

Hello fellow Wikipedians,

I have just modified one external link on Muscle-type nicotinic receptor. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:

• Added archive https://web.archive.org/web/20071227192643/http://www.neurosci.pharm.utoledo.edu/MBC3320/nicotinic.htm to http://www.neurosci.pharm.utoledo.edu/MBC3320/nicotinic.htm

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}} (last update: 5 June 2024).

• If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
• If you found an error with any archives or the URLs themselves, you can fix them with this tool.

Cheers.—InternetArchiveBot (Report bug) 22:37, 8 February 2018 (UTC)

persistence of fetal receptor type in healthy human muscle?

Until recently, my knowledge was that the fetal receptor gets replaced entirely by its adult counterpart as the neuromuscular junction matures, and as a result, the fetal type will only be expressed in denervated muscles and during fetal development (hence its name!) but not play any role in the function of intact neuromuscular junctions.

However, this seems to be accurate in rats and mice but not in humans. According to a few studies on congenital myasthenic syndromes, the healthy human NMJ does indeed retain a small number of fetal-type receptors which increase the chance of survival in forms of CMS where the epsilon subunit is mutated.

https://pubmed.ncbi.nlm.nih.gov/11408331/

Besides, mice and rats seem to continue expressing the fetal receptor at small numbers in extraocular muscles but not anywhere else. Which won't help them survive in case of CHRNE mutations as it doesn't prevent or alleviate respiratory failure.

Nevertheless, many papers on NMJ development use rodent models and generalize them to humans, apparently without regard for these differences. Similarly for studies on pharmacologic agents and neurotoxins, as a few of them interact differently with fetal and adult muscle nAChRs. Aren't any other "suitable" laboratory animals known which have more human-like NMJs? (Maybe organoids?)

Anyway, if this is indeed true (sufficiently reproduced) it may be worth mentioning in the article. --2003:E7:7706:7A82:88BC:61A9:9444:D598 (talk) 21:13, 14 April 2022 (UTC)

PAMs and NAMs

Despite their therapeutic potential, allosteric modulators of this receptor are indeed not well-known. However, there seem to be some drugs used for entirely different purposes which do this as a side effect.

For example, here is a paper on monoamine uptake inhibitors interacting with muscle and neuronal nAChRs, and if I understand the abstract correctly, those act as negative allosteric modulators at the muscle nAChR:

https://pubmed.ncbi.nlm.nih.gov/11526465/

Similarly for endogenous serotonin, at least according to the first "similar article" in the list below.

Importantly, these are studies on rodent NMJ models again, which in the absence of detailed knowledge about the mechanism may or may not generalize to humans.

There are also papers examining the influence of general anaesthetics and other drugs on neuromuscular block during general anaesthesia. What I remember form those is that certain substances influence the binding of the neuromuscular blocking agents to the receptor. E.g. nitrous oxide and xenon tend to increase binding affinity and thus the onset and duration of neuromuscular block. Do they do this only to antagonists, or to acetylcholine as well? In the latter case they would qualify as PAMs. (The alleged ethymology of the name "laughing gas" for nitrous oxide stemming from diaphragm spasms would fit to such a mechanism of action, at least.) --2003:E7:7706:7A82:88BC:61A9:9444:D598 (talk) 22:03, 14 April 2022 (UTC)